Kardi Ai Raises CZK 130M Series A at CZK 600M Valuation

Czech medtech startup Kardi Ai has raised CZK 130 million in a Series A round that values the company at CZK 600 million, money it will spend on European and Asian expansion and on predictive models designed to estimate cardiac arrhythmia risk before symptoms appear. German health-technology venture fund Callisto Health led the round, the company announced on November 11, 2026.

The company describes the financing as the largest investment round to date among Czech medtech startups. That claim positions a small Prague-based firm against a national sector that has rarely produced rounds of this size, and it signals to international investors that Central European health technology can attract cross-border capital at scale.

Who put money in?

The round extends a backer list built over three prior years. The Seed Starter programs of Česká spořitelna and Slovenská sporiteľňa participated, alongside BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels.

Two of those investors have history with the company. Purple Ventures led Kardi Ai's seed round in 2023. BrightCap Ventures led its pre-seed round in 2022. The Series A therefore represents a continuation of existing investor confidence rather than a fresh bet by outsiders alone, with Callisto Health entering as the new lead.

What does the system actually do?

Kardi Ai combines three components: a sports chest strap containing an electrocardiogram sensor, a mobile application, and AI analysis of the recordings. Users wear the device during ordinary daily activities, view results in the app, and can make those results available to a physician.

The system does not itself establish a diagnosis. It supplies information that supports decisions about further care. According to the company, longer recordings can help capture intermittently occurring arrhythmias that a short clinical examination may miss — the core clinical argument for continuous, consumer-grade monitoring instead of snapshot testing in a doctor's office.

How many detections has it produced?

The deployment numbers give the round its substance. Kardi Ai reports working with more than 70 hospitals and more than 20 corporate and employee-benefit partners in Czechia. Its technology serves more than 6,000 users.

The clinical signal inside that user base is the figure that matters. Approximately one-quarter of users received an alert about a possible arrhythmia during long-term monitoring. More than 500 detections were assessed as critical. Those detections — surfaced in people going about daily life, not in clinics — form the evidence base the company will carry into new markets and into its next product phase.

Where is the company expanding?

Kardi Ai already operates in five European markets: Czechia, Slovakia, Poland, Romania and Bulgaria. It is preparing a German launch after completing pilot projects there. Germany is Europe's largest healthcare market, and the launch follows pilots rather than preceding them.

The Slovak entry shows the distribution model. After entering through a local distributor, Kardi Ai reports working with more than 20 physicians in the country, mainly cardiologists.

Asia is the larger growth bet. India's drug regulator, CDSCO, issued Kardi Ai an MD-15 import licence covering both its hardware and software in July 2026. The Indian entry is planned to begin in Hyderabad, where the company says discussions with healthcare partners and commercial and logistics preparations are continuing. Operations are planned for the fourth quarter of 2026.

Two further regulatory tracks run in parallel. Kardi Ai reports holding a medical-device registration certificate from the UAE Ministry of Health and Prevention and is preparing market entry there. Medical-device approval in Singapore remains in progress. The company plans to use Singapore as an entry point to Southeast Asia, with the Philippines, Indonesia and Vietnam identified as subsequent target markets.

What will the predictive models change?

The research agenda separates this round from a pure expansion story. Kardi Ai plans predictive models that use data from several measurements to estimate arrhythmia risk, extending the current technology beyond long-term monitoring and evaluation of heart rhythm toward earlier warning.

The models remain in development. They must undergo expert validation and the applicable regulatory approval process before use in healthcare practice. That requirement is not a formality: predictive risk estimation claims a different level of clinical authority than monitoring, and regulators treat it accordingly.

Chief executive Vlastimil Hrabal said the development goal is to warn of elevated risk before an arrhythmia manifests, with the new capital supporting validation across global markets and different patient demographics. Validation across demographics matters because arrhythmia risk models trained on one population do not automatically transfer to another — a constraint that shapes both the regulatory path and the clinical credibility of the product in India, Southeast Asia and the Gulf.

Callisto Health managing director Stefan Eckhardt framed the investment case around the existing product. He said the product combines a certified medical device, ease of use and medical benefit, and noted its existing use in routine practice in Central and Eastern Europe.

What is at stake in the round?

The financing ties international expansion to a distinct development hurdle. Market launches can build on the existing monitoring system, which already carries certifications and clinical use. Clinical use of the proposed earlier-warning models depends on completing validation and regulatory approval — a slower, less predictable track.

The two-track structure defines the next phase for Kardi Ai. The CZK 130 million funds hospitals, distributors and regulators in at least seven prospective markets on one track; on the other, it funds the evidence required to move from detecting arrhythmias to predicting them. If the predictive models clear validation, Kardi Ai shifts from a monitoring hardware-and-software business into risk-stratified preventive cardiology; if they do not, the company still holds a certified monitoring platform with six thousand users and a documented record of more than 500 critical detections.